We could not find any results for:
Make sure your spelling is correct or try broadening your search.
An all-new interview with Scott Sand, CEO of Ingen Technologies, Inc. is also available on WallSt.net NEW YORK, Feb. 12 /PRNewswire/ -- The Analyst's Review is a daily podcast hosted by...
NEW YORK, Jan. 18 /PRNewswire/ -- The Analyst's Review is a daily podcast hosted by WallSt.net editor, Henry Truc that airs every morning at 9 a.m. EST on http://radio.wallst.net/profile.asp?id=1...
ADDITIONAL RESOURCES: Video, hard copy requests, contact information and more available at: http://www.prnewswire.com/broadcast/23534/consumer.html NEW YORK, November 17 /PRNewswire/ -- THIS IS...
SOUTH SAN FRANCISCO, Calif., Sept. 11 /PRNewswire-FirstCall/ -- Genentech, Inc. today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for a...
SOUTH SAN FRANCISCO, Calif., Aug. 17 /PRNewswire-FirstCall/ -- The Genentech Foundation for Biomedical Sciences announced today that its Board of Directors has awarded 25 grants in 2006 totaling...
CHICAGO, Dec. 7 /PRNewswire/ -- Seven Summits Research issues the following Morning Update at 8:30 AM EST with new PriceWatch Alerts for key stocks. Before the open PriceWatch Alerts for DNA...
Tiki Barber, Shaun Alexander and Others Join Merril Hoge and Dedicate 2005 Season to Raising Awareness of One of the Fastest Growing Cancers in the US NEW YORK, Sept. 21 /PRNewswire-FirstCall/...
Genentech Foundation for Biomedical Sciences Bolsters Innovation in Health Science Education With $1.2 Million for Bay Area Programs SOUTH SAN FRANCISCO, Calif., July 29 /PRNewswire-FirstCall/...
Preliminary Phase IIb Study Showed Rituxan Improved Symptoms in Rheumatoid Arthritis Patients Who Failed One or More Disease-Modifying Anti-Rheumatic Drugs Improvement Shown to Be Independent of...
Addendum to Genentech Announces Fourth Quarter and Full Year 2004 Results (FINANCIAL TABLES) SOUTH SAN FRANCISCO, Calif., Jan. 10 /PRNewswire-FirstCall/ -- GENENTECH, INC. CONDENSED...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions